Other Vaccines - Central & Western Europe

  • Central & Western Europe
  • In Central & Western Europe, the revenue in the Other Vaccines market is estimated to reach US$6.07bn in 2024.
  • The market is expected to exhibit a compound annual growth rate (CAGR 2024-2029) of 10.39%, leading to a market volume of US$9.95bn by 2029.
  • When compared globally, United States is projected to generate the highest revenue, amounting to US$24,730.00m in 2024.
  • In Central & Western Europe, Germany is leading the way in the development and distribution of innovative vaccines in the Other Vaccines market.

Key regions: Australia, Brazil, United Kingdom, Europe, Canada

 
Market
 
Region
 
Region comparison
 
Currency
 

Analyst Opinion

The Other Vaccines market in Central & Western Europe has been showing steady growth in recent years, driven by several factors such as rising healthcare expenditure, increasing awareness about preventive healthcare, and the growing prevalence of infectious diseases.

Customer preferences:
Customers in Central & Western Europe are increasingly seeking out vaccines that offer protection against a wider range of diseases. This has led to a growing demand for combination vaccines that offer protection against multiple diseases in a single shot. Additionally, there is a rising preference for vaccines that have fewer side effects and are more convenient to administer.

Trends in the market:
The market for Other Vaccines in Central & Western Europe is being driven by a number of key trends. One of the most notable trends is the increasing demand for vaccines that offer protection against a wider range of diseases. This has led to a growing interest in combination vaccines, which offer protection against multiple diseases in a single shot. Another trend is the growing use of vaccines in adult populations, particularly for diseases such as influenza and pneumonia. Finally, there is a growing trend towards the use of vaccines in emerging markets, as governments seek to improve public health outcomes and reduce the burden of infectious diseases.

Local special circumstances:
The market for Other Vaccines in Central & Western Europe is characterised by a number of local special circumstances. For example, some countries in the region have higher rates of certain infectious diseases, such as hepatitis B, which has led to a higher demand for vaccines that offer protection against these diseases. Additionally, some countries in the region have more advanced healthcare systems and higher levels of healthcare spending, which has led to a greater availability of vaccines and a higher rate of vaccination.

Underlying macroeconomic factors:
The growth of the Other Vaccines market in Central & Western Europe is being driven by a number of underlying macroeconomic factors. One of the most important of these is rising healthcare expenditure, which has led to increased investment in preventive healthcare measures such as vaccination. Additionally, there is a growing awareness of the importance of preventive healthcare, which has led to an increased demand for vaccines. Finally, the growing prevalence of infectious diseases in the region has also contributed to the growth of the market, as governments and healthcare providers seek to reduce the burden of these diseases on public health.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

Overview

  • Revenue
  • Analyst Opinion
  • Global Comparison
  • Methodology
  • Key Market Indicators
Please wait

Contact

Get in touch with us. We are happy to help.
Statista Locations
Contact Meredith Alda
Meredith Alda
Sales Manager– Contact (United States)

Mon - Fri, 9am - 6pm (EST)

Contact Yolanda Mega
Yolanda Mega
Operations Manager– Contact (Asia)

Mon - Fri, 9am - 5pm (SGT)

Contact Ayana Mizuno
Ayana Mizuno
Junior Business Development Manager– Contact (Asia)

Mon - Fri, 10:00am - 6:00pm (JST)

Contact Lodovica Biagi
Lodovica Biagi
Director of Operations– Contact (Europe)

Mon - Fri, 9:30am - 5pm (GMT)

Contact Carolina Dulin
Carolina Dulin
Group Director - LATAM– Contact (Latin America)

Mon - Fri, 9am - 6pm (EST)